Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)Alba A. Brandes, Mario Ermani|British Journal of Cancer|2006Cited by 228